Study identification

EU PAS number

EUPAS1000000079

Study ID

1000000079

Official title and acronym

Real world management of pain: Do patient-specific factors influence treatment decisions and its outcomes? (RELIEF)

DARWIN EU® study

No

Study countries

Bosnia and Herzegovina
Croatia
Czechia
North Macedonia
Serbia

Study description

Pain of any type is the most common reason to consult the doctor and is one of the leading domains of disability worldwide. It is estimated that 40–60% of patients with chronic pain have inadequate management of their pain, while also management of acute pain remains inadequate across various treatment settings. Thus, epidemiological study RELIEF explored if and how patient-specific factors play a role in the selection of medications for pain management, especially NSAIDs and paracetamol/tramadol combination, in five European countries. As quality of life is increasingly being recognized as one of the most important parameters to be measured in the evaluation of pain management therapies, the study has additionally observed influence of pain and corresponding treatment choices on patient’s quality of life in usual care settings. Obtained findings have been transferred to professional public in order to improve pain management of any type and duration in daily practice.

Study status

Finalised
Research institutions and networks

Institutions

University Clinic for Traumatology, Orthopaedic Diseases, Anaesthesia, Reanimation, Intensive Care and Emergency Center, Skopje, North Macedonia
Privatna ortopedska ordinacija “Prof.dr. Mirza Biščević“, Sarajevo; Bosnia and Herzegovina; Klinički centar Vojvodine, Novi Sad, Serbia; Centrum pro léčení a výzkum bolestivých stavů při Klinice rehabilitace a tělovýchovného lékařství, Fakultní nemocnice v Motole, Prague, Czecha; Klinički bolnički centar Zagreb, Zagreb, Croatia; University Clinic for Traumatology, Orthopaedic Diseases, Anaesthesia, Reanimation, Intensive Care and Emergency Center, Skopje, North Macedonia.

Contact details

Antonio Gavrilovski

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Representative offices or companies of Krka d.d., Novo mesto in Bosnia and Herzegovina, Croatia, Czech Republic, North Macedonia and Serbia.
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable